Cerebral glucose metabolism during pharmacologic studies: Test-retest under placebo conditions

Mark E. Schmidt, Monique Ernst, John A. Matochik, Jose Ma Maisog, Bai Shen Pan, Alan J. Zametkin, William Z. Potter

Research output: Contribution to journalArticlepeer-review

Abstract

The reliability of serial [18F]fluorodeoxyglucose (FDG) PET scans for psychopharmacologic studies was tested by using placebo infusions. Methods: FDG scans were obtained before and after a 30 min placebo infusion (n = 10; Group 1) or after each of two bolus infusions with placebo (n = 8; Group 2). Subjects performed a continuous performance task (CPT) during each scan. Cardiovascular measures and ratings of anxiety were obtained in all subjects. Samples for determination of plasma norepinephrine (NE) were taken at multiple time points in Group 1. Results: A slight increase in apparent global metabolism occurred between scans in both Groups 1 and 2. A few regions significantly increased in both groups. While an apparent increase in sympathetic activity occurred during the placebo infusion, neither NE levels, anxiety ratings nor cardiovascular measures correlated with global or regional FDG uptake. Conclusion: Test-retest differences of global and regional glucose metabolism were highly consistent across two experimental designs. While increases in cerebral glucose metabolism appeared to occur during the second scan, differences between scans were small. This method may offer advantages for selected psychopharmacologic studies.

Original languageEnglish (US)
Pages (from-to)1142-1149
Number of pages8
JournalJournal of Nuclear Medicine
Volume37
Issue number7
StatePublished - Jul 1 1996

Keywords

  • FDG-PET
  • placebo
  • validation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Cerebral glucose metabolism during pharmacologic studies: Test-retest under placebo conditions'. Together they form a unique fingerprint.

Cite this